메뉴 건너뛰기




Volumn 221, Issue , 2016, Pages 60-74

A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients

Author keywords

Economic evaluation; Efficacy; Hypertension; Olmesartan; Review; Safety

Indexed keywords

ALISKIREN; AMLODIPINE; AZELNIDIPINE; CANDESARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

EID: 84977664832     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.115     Document Type: Review
Times cited : (14)

References (85)
  • 3
    • 0038460302 scopus 로고    scopus 로고
    • The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    • [3] Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003), 2560–2572.
    • (2003) JAMA , vol.289 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3    Cushman, W.C.4    Green, L.A.5    Izzo, J.L.6
  • 4
    • 34547841317 scopus 로고    scopus 로고
    • Essential hypertension
    • [4] Messerli, F.H., Williams, B., Ritz, E., Essential hypertension. Lancet 370 (2007), 591–603.
    • (2007) Lancet , vol.370 , pp. 591-603
    • Messerli, F.H.1    Williams, B.2    Ritz, E.3
  • 5
    • 0038690424 scopus 로고    scopus 로고
    • Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000
    • [5] Hajjar, I., Kotchen, T.A., Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 290 (2003), 199–206.
    • (2003) JAMA , vol.290 , pp. 199-206
    • Hajjar, I.1    Kotchen, T.A.2
  • 6
    • 0032513878 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
    • [6] Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998), 1755–1762.
    • (1998) Lancet , vol.351 , pp. 1755-1762
    • Hansson, L.1    Zanchetti, A.2    Carruthers, S.G.3    Dahlof, B.4    Elmfeldt, D.5    Julius, S.6
  • 7
    • 0034627183 scopus 로고    scopus 로고
    • Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
    • [7] Neal, B., MacMahon, S., Chapman, N., Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356 (2000), 1955–1964.
    • (2000) Lancet , vol.356 , pp. 1955-1964
    • Neal, B.1    MacMahon, S.2    Chapman, N.3
  • 8
    • 0035979589 scopus 로고    scopus 로고
    • Manipulation of the renin–angiotensin system
    • [8] Givertz, M.M., Manipulation of the renin–angiotensin system. Circulation 104 (2001), E14–E18.
    • (2001) Circulation , vol.104 , pp. E14-E18
    • Givertz, M.M.1
  • 9
    • 34748859681 scopus 로고    scopus 로고
    • The intrarenal renin–angiotensin system: from physiology to the pathobiology of hypertension and kidney disease
    • [9] Kobori, H., Nangaku, M., Navar, L.G., Nishiyama, A., The intrarenal renin–angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59 (2007), 251–287.
    • (2007) Pharmacol. Rev. , vol.59 , pp. 251-287
    • Kobori, H.1    Nangaku, M.2    Navar, L.G.3    Nishiyama, A.4
  • 10
    • 0037165229 scopus 로고    scopus 로고
    • The role of the renin–angiotensin system in the development of cardiovascular disease
    • (discussion 10 A)
    • [10] Unger, T., The role of the renin–angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. 89 (2002), 3 A–9 A (discussion 10 A).
    • (2002) Am. J. Cardiol. , vol.89 , pp. 3 A-9 A
    • Unger, T.1
  • 11
    • 0033736285 scopus 로고    scopus 로고
    • A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension
    • [11] Lacourciere, Y., A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin. Ther. 22 (2000), 1213–1224.
    • (2000) Clin. Ther. , vol.22 , pp. 1213-1224
    • Lacourciere, Y.1
  • 12
    • 0031932886 scopus 로고    scopus 로고
    • A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension
    • [12] Mimran, A., Ruilope, L., Kerwin, L., Nys, M., Owens, D., Kassler-Taub, K., et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J. Hum. Hypertens. 12 (1998), 203–208.
    • (1998) J. Hum. Hypertens. , vol.12 , pp. 203-208
    • Mimran, A.1    Ruilope, L.2    Kerwin, L.3    Nys, M.4    Owens, D.5    Kassler-Taub, K.6
  • 13
    • 0034951771 scopus 로고    scopus 로고
    • Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist
    • [13] Puchler, K., Laeis, P., Stumpe, K.O., Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J. Hypertens. Suppl. 19 (2001), S41–S48.
    • (2001) J. Hypertens. Suppl. , vol.19 , pp. S41-S48
    • Puchler, K.1    Laeis, P.2    Stumpe, K.O.3
  • 14
    • 14744290689 scopus 로고    scopus 로고
    • Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals
    • [14] Oparil, S., Silfani, T.N., Walker, J.F., Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am. J. Hypertens. 18 (2005), 287–294.
    • (2005) Am. J. Hypertens. , vol.18 , pp. 287-294
    • Oparil, S.1    Silfani, T.N.2    Walker, J.F.3
  • 15
    • 79959334521 scopus 로고    scopus 로고
    • Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
    • [15] Calhoun, D.A., Jones, D., Textor, S., Goff, D.C., Murphy, T.P., Toto, R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117 (2008), e510–e526.
    • (2008) Circulation , vol.117 , pp. e510-e526
    • Calhoun, D.A.1    Jones, D.2    Textor, S.3    Goff, D.C.4    Murphy, T.P.5    Toto, R.D.6
  • 16
    • 69149107165 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    • (W64)
    • [16] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151 (2009), 264–269 (W64).
    • (2009) Ann. Intern. Med. , vol.151 , pp. 264-269
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 17
    • 0026524708 scopus 로고
    • Incorporating variations in the quality of individual randomized trials into meta-analysis
    • [17] Detsky, A.S., Naylor, C.D., O'Rourke, K., McGeer, A.J., L'Abbe, K.A., Incorporating variations in the quality of individual randomized trials into meta-analysis. J. Clin. Epidemiol. 45 (1992), 255–265.
    • (1992) J. Clin. Epidemiol. , vol.45 , pp. 255-265
    • Detsky, A.S.1    Naylor, C.D.2    O'Rourke, K.3    McGeer, A.J.4    L'Abbe, K.A.5
  • 18
    • 0642286336 scopus 로고    scopus 로고
    • Examining the value and quality of health economic analyses: implications of utilizing the QHES
    • [18] Ofman, J.J., Sullivan, S.D., Neumann, P.J., Chiou, C.F., Henning, J.M., Wade, S.W., et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. 9 (2003), 53–61.
    • (2003) J. Manag. Care Pharm. , vol.9 , pp. 53-61
    • Ofman, J.J.1    Sullivan, S.D.2    Neumann, P.J.3    Chiou, C.F.4    Henning, J.M.5    Wade, S.W.6
  • 19
    • 79251590265 scopus 로고    scopus 로고
    • The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure
    • [19] Bakris, G.L., Sica, D., Weber, M., White, W.B., Roberts, A., Perez, A., et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J. Clin. Hypertens. (Greenwich) 13 (2011), 81–88.
    • (2011) J. Clin. Hypertens. (Greenwich) , vol.13 , pp. 81-88
    • Bakris, G.L.1    Sica, D.2    Weber, M.3    White, W.B.4    Roberts, A.5    Perez, A.6
  • 20
    • 0034951613 scopus 로고    scopus 로고
    • Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives
    • [20] Ball, K.J., Williams, P.A., Stumpe, K.O., Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J. Hypertens. Suppl. 19 (2001), S49–S56.
    • (2001) J. Hypertens. Suppl. , vol.19 , pp. S49-S56
    • Ball, K.J.1    Williams, P.A.2    Stumpe, K.O.3
  • 21
    • 33645543047 scopus 로고    scopus 로고
    • Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals
    • [21] Brunner, H.R., Arakawa, K., Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig. 26 (2006), 185–193.
    • (2006) Clin Drug Investig. , vol.26 , pp. 185-193
    • Brunner, H.R.1    Arakawa, K.2
  • 22
    • 0043172552 scopus 로고    scopus 로고
    • Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension
    • [22] Brunner, H.R., Stumpe, K.O., Januszewicz, A., Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin. Drug Investig. 23 (2003), 419–430.
    • (2003) Clin. Drug Investig. , vol.23 , pp. 419-430
    • Brunner, H.R.1    Stumpe, K.O.2    Januszewicz, A.3
  • 23
    • 0038042008 scopus 로고    scopus 로고
    • Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension
    • [23] Chrysant, S.G., Marbury, T.C., Robinson, T.D., Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J. Hum. Hypertens., 2003, 425–432.
    • (2003) J. Hum. Hypertens. , pp. 425-432
    • Chrysant, S.G.1    Marbury, T.C.2    Robinson, T.D.3
  • 24
    • 33746158062 scopus 로고    scopus 로고
    • Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate
    • [24] Chrysant, S.G., Marbury, T.C., Silfani, T.N., Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press. Monit., 2006, 135–141.
    • (2006) Blood Press. Monit. , pp. 135-141
    • Chrysant, S.G.1    Marbury, T.C.2    Silfani, T.N.3
  • 25
    • 18444416063 scopus 로고    scopus 로고
    • Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring
    • [25] Destro, M., Scabrosetti, R., Vanasia, A., Mugellini, A., Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Adv. Ther., 2005, 32–43.
    • (2005) Adv. Ther. , pp. 32-43
    • Destro, M.1    Scabrosetti, R.2    Vanasia, A.3    Mugellini, A.4
  • 26
    • 84867886614 scopus 로고    scopus 로고
    • Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension
    • [26] Flack, J.M., Graff, A., Li, W., Chavanu, K.J., Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. Postgrad. Med. 124 (2012), 59–70.
    • (2012) Postgrad. Med. , vol.124 , pp. 59-70
    • Flack, J.M.1    Graff, A.2    Li, W.3    Chavanu, K.J.4
  • 27
    • 34247181619 scopus 로고    scopus 로고
    • Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension
    • [27] Giles, T.D., Oparil, S., Silfani, T.N., Wang, A., Walker, J.F., Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J. Clin. Hypertens. (Greenwich) 9 (2007), 187–195.
    • (2007) J. Clin. Hypertens. (Greenwich) , vol.9 , pp. 187-195
    • Giles, T.D.1    Oparil, S.2    Silfani, T.N.3    Wang, A.4    Walker, J.F.5
  • 28
    • 22544483548 scopus 로고    scopus 로고
    • Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in chinese patients
    • [28] Liau, C.S., Lee, C.M., Sheu, S.H., Ueng, K.C., Chien, K.L., Su, T.C., et al. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in chinese patients. Clin. Drug Investig., 2005, 473–479.
    • (2005) Clin. Drug Investig. , pp. 473-479
    • Liau, C.S.1    Lee, C.M.2    Sheu, S.H.3    Ueng, K.C.4    Chien, K.L.5    Su, T.C.6
  • 29
    • 77958463672 scopus 로고    scopus 로고
    • Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study
    • [29] Malacco, E., Omboni, S., Volpe, M., Auteri, A., Zanchetti, A., Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J. Hypertens. 28 (2010), 2342–2350.
    • (2010) J. Hypertens. , vol.28 , pp. 2342-2350
    • Malacco, E.1    Omboni, S.2    Volpe, M.3    Auteri, A.4    Zanchetti, A.5
  • 30
    • 34748894914 scopus 로고    scopus 로고
    • Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension
    • [30] Mallion, J.M., Heagerty, A., Laeis, P., Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J. Hypertens. 25 (2007), 2168–2177.
    • (2007) J. Hypertens. , vol.25 , pp. 2168-2177
    • Mallion, J.M.1    Heagerty, A.2    Laeis, P.3
  • 31
    • 85027903203 scopus 로고    scopus 로고
    • Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension
    • [31] Mallion, J.M., Omboni, S., Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. J. Hypertens., 2010, e45.
    • (2010) J. Hypertens. , pp. e45
    • Mallion, J.M.1    Omboni, S.2
  • 32
    • 0034760610 scopus 로고    scopus 로고
    • Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
    • (318)
    • [32] Oparil, S., Williams, D., Chrysant, S.G., Marbury, T.C., Neutel, J., Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J. Clin. Hypertens. (Greenwich) 3 (2001), 283–291 (318).
    • (2001) J. Clin. Hypertens. (Greenwich) , vol.3 , pp. 283-291
    • Oparil, S.1    Williams, D.2    Chrysant, S.G.3    Marbury, T.C.4    Neutel, J.5
  • 33
    • 84866512636 scopus 로고    scopus 로고
    • Efficacy/safety of olmesartan medoxomil versus losartan potassium in naive versus previously treated subjects with hypertension
    • [33] Punzi, H.A., Lewin, A., Li, W., Chavanu, K.J., Efficacy/safety of olmesartan medoxomil versus losartan potassium in naive versus previously treated subjects with hypertension. Adv. Ther. 29 (2012), 524–537.
    • (2012) Adv. Ther. , vol.29 , pp. 524-537
    • Punzi, H.A.1    Lewin, A.2    Li, W.3    Chavanu, K.J.4
  • 34
    • 12744269551 scopus 로고    scopus 로고
    • Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan
    • [34] Smith, D.H., Dubiel, R., Jones, M., Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am. J. Cardiovasc. Drugs 5 (2005), 41–50.
    • (2005) Am. J. Cardiovasc. Drugs , vol.5 , pp. 41-50
    • Smith, D.H.1    Dubiel, R.2    Jones, M.3
  • 35
    • 0036105846 scopus 로고    scopus 로고
    • Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs
    • [35] Stumpe, K.O., Ludwig, M., Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J. Hum. Hypertens. 16:Suppl. 2 (2002), S24–S28.
    • (2002) J. Hum. Hypertens. , vol.16 , pp. S24-S28
    • Stumpe, K.O.1    Ludwig, M.2
  • 36
    • 79952275464 scopus 로고    scopus 로고
    • A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension
    • [36] Weir, M.R., Punzi, H.A., Flack, J.M., Stoakes, K.A., Chavanu, K.J., Li, W., et al. A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. Postgrad. Med. 123 (2011), 80–87.
    • (2011) Postgrad. Med. , vol.123 , pp. 80-87
    • Weir, M.R.1    Punzi, H.A.2    Flack, J.M.3    Stoakes, K.A.4    Chavanu, K.J.5    Li, W.6
  • 37
    • 79953239152 scopus 로고    scopus 로고
    • Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension
    • [37] White, W.B., Weber, M.A., Sica, D., Bakris, G.L., Perez, A., Cao, C., et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 57 (2011), 413–420.
    • (2011) Hypertension , vol.57 , pp. 413-420
    • White, W.B.1    Weber, M.A.2    Sica, D.3    Bakris, G.L.4    Perez, A.5    Cao, C.6
  • 38
    • 34547308715 scopus 로고    scopus 로고
    • Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study
    • [38] Barrios, V., Boccanelli, A., Ewald, S., Girerd, X., Heagerty, A., Krzesinski, J.M., et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin. Drug Investig. 27 (2007), 545–558.
    • (2007) Clin. Drug Investig. , vol.27 , pp. 545-558
    • Barrios, V.1    Boccanelli, A.2    Ewald, S.3    Girerd, X.4    Heagerty, A.5    Krzesinski, J.M.6
  • 39
    • 67650302856 scopus 로고    scopus 로고
    • Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study
    • [39] Barrios, V., Brommer, P., Haag, U., Calderon, A., Escobar, C., Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig. 29 (2009), 427–439.
    • (2009) Clin. Drug Investig. , vol.29 , pp. 427-439
    • Barrios, V.1    Brommer, P.2    Haag, U.3    Calderon, A.4    Escobar, C.5
  • 40
    • 74049152360 scopus 로고    scopus 로고
    • Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study
    • [40] Barrios, V., Escobar, C., Calderon, A., Bohm, M., Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. Vasc. Health Risk Manag. 5 (2009), 723–729.
    • (2009) Vasc. Health Risk Manag. , vol.5 , pp. 723-729
    • Barrios, V.1    Escobar, C.2    Calderon, A.3    Bohm, M.4
  • 41
    • 84920908365 scopus 로고    scopus 로고
    • Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone
    • [41] Bilo, G., Koch, W., Hoshide, S., Parati, G., Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone. Hypertens. Res. 37 (2014), 836–844.
    • (2014) Hypertens. Res. , vol.37 , pp. 836-844
    • Bilo, G.1    Koch, W.2    Hoshide, S.3    Parati, G.4
  • 42
    • 70349151351 scopus 로고    scopus 로고
    • Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study
    • [42] Chrysant, S.G., Chavanu, K.J., Xu, J., Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am. J.Cardiovasc. Drugs, 2009, 241–251.
    • (2009) Am. J.Cardiovasc. Drugs , pp. 241-251
    • Chrysant, S.G.1    Chavanu, K.J.2    Xu, J.3
  • 43
    • 43549100189 scopus 로고    scopus 로고
    • The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study
    • [43] Chrysant, S.G., Melino, M., Karki, S., Lee, J., Heyrman, R., The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther., 2008, 587–604.
    • (2008) Clin. Ther. , pp. 587-604
    • Chrysant, S.G.1    Melino, M.2    Karki, S.3    Lee, J.4    Heyrman, R.5
  • 44
    • 70349973807 scopus 로고    scopus 로고
    • Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension
    • [44] Chrysant, S.G., Oparil, S., Melino, M., Karki, S., Lee, J., Heyrman, R., Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J. Clin. Hypertens. (Greenwich), 2009, 475–482.
    • (2009) J. Clin. Hypertens. (Greenwich) , pp. 475-482
    • Chrysant, S.G.1    Oparil, S.2    Melino, M.3    Karki, S.4    Lee, J.5    Heyrman, R.6
  • 45
    • 1442299290 scopus 로고    scopus 로고
    • Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
    • [45] Chrysant, S.G., Weber, M.A., Wang, A.C., Hinman, D.J., Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens., 2004, 252–259.
    • (2004) Am. J. Hypertens. , pp. 252-259
    • Chrysant, S.G.1    Weber, M.A.2    Wang, A.C.3    Hinman, D.J.4
  • 46
    • 84882977181 scopus 로고    scopus 로고
    • Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies
    • [46] Derosa, G., Cicero, A.F., Carbone, A., Querci, F., Fogari, E., D'Angelo, A., et al. Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Expert Opin. Drug Saf. 12 (2013), 621–629.
    • (2013) Expert Opin. Drug Saf. , vol.12 , pp. 621-629
    • Derosa, G.1    Cicero, A.F.2    Carbone, A.3    Querci, F.4    Fogari, E.5    D'Angelo, A.6
  • 47
    • 84881660487 scopus 로고    scopus 로고
    • Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension
    • [47] Ding, S., Liu, J., Fu, Q., Zheng, Y., Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension. Arch. Gerontol. Geriatr., 2013, 423–427.
    • (2013) Arch. Gerontol. Geriatr. , pp. 423-427
    • Ding, S.1    Liu, J.2    Fu, Q.3    Zheng, Y.4
  • 48
    • 77954626007 scopus 로고    scopus 로고
    • Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study
    • [48] Fogari, R., Taddei, S., Holm-Bentzen, M., Baszak, J., Melani, L., Schumacher, K., Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Clin. Drug Investig. 30 (2010), 581–597.
    • (2010) Clin. Drug Investig. , vol.30 , pp. 581-597
    • Fogari, R.1    Taddei, S.2    Holm-Bentzen, M.3    Baszak, J.4    Melani, L.5    Schumacher, K.6
  • 49
    • 33845602177 scopus 로고    scopus 로고
    • Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy
    • [49] Fogari, R., Zoppi, A., Mugellini, A., Preti, P., Destro, M., Rinaldi, A., et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv. Ther., 2006, 680–695.
    • (2006) Adv. Ther. , pp. 680-695
    • Fogari, R.1    Zoppi, A.2    Mugellini, A.3    Preti, P.4    Destro, M.5    Rinaldi, A.6
  • 50
    • 41249095681 scopus 로고    scopus 로고
    • Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study
    • [50] Fogari, R., Zoppi, A., Mugellini, A., Preti, P., Destro, M., Rinaldi, A., et al. Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Curr. Ther. Res. Clin. Exp., 2008, 1–15.
    • (2008) Curr. Ther. Res. Clin. Exp. , pp. 1-15
    • Fogari, R.1    Zoppi, A.2    Mugellini, A.3    Preti, P.4    Destro, M.5    Rinaldi, A.6
  • 51
    • 84858631158 scopus 로고    scopus 로고
    • Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients
    • [51] Fogari, R., Zoppi, A., Mugellini, A., Preti, P., Perrone, T., Maffioli, P., et al. Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. Expert. Opin. Pharmacother. 13 (2012), 629–636.
    • (2012) Expert. Opin. Pharmacother. , vol.13 , pp. 629-636
    • Fogari, R.1    Zoppi, A.2    Mugellini, A.3    Preti, P.4    Perrone, T.5    Maffioli, P.6
  • 52
    • 83055176358 scopus 로고    scopus 로고
    • 24-Hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy
    • [52] Izzo, J.L. Jr., Chrysant, S.G., Kereiakes, D.J., Littlejohn Iii, T., Oparil, S., Melino, M., et al. 24-Hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J. Clin. Hypertens. (Greenwich) 13 (2011), 873–880.
    • (2011) J. Clin. Hypertens. (Greenwich) , vol.13 , pp. 873-880
    • Izzo, J.L.1    Chrysant, S.G.2    Kereiakes, D.J.3    Littlejohn Iii, T.4    Oparil, S.5    Melino, M.6
  • 53
    • 84862810814 scopus 로고    scopus 로고
    • Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension
    • [53] Kereiakes, D.J., Chrysant, S.G., Izzo, J.L. Jr., Littlejohn, T. 3rd, Oparil, S., Melino, M., et al. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J. Clin. Hypertens. (Greenwich) 14 (2012), 149–157.
    • (2012) J. Clin. Hypertens. (Greenwich) , vol.14 , pp. 149-157
    • Kereiakes, D.J.1    Chrysant, S.G.2    Izzo, J.L.3    Littlejohn, T.4    Oparil, S.5    Melino, M.6
  • 54
    • 35448989395 scopus 로고    scopus 로고
    • Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate
    • [54] Kereiakes, D.J., Neutel, J.M., Punzi, H.A., Xu, J., Lipka, L.J., Dubiel, R., Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am. J. Cardiovasc. Drugs 7 (2007), 361–372.
    • (2007) Am. J. Cardiovasc. Drugs , vol.7 , pp. 361-372
    • Kereiakes, D.J.1    Neutel, J.M.2    Punzi, H.A.3    Xu, J.4    Lipka, L.J.5    Dubiel, R.6
  • 55
    • 84876956841 scopus 로고    scopus 로고
    • Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension
    • [55] Lin, T.H., Tsai, C.D., Pan, J.P., Hou, C.J., Hsia, C.H., Tsai, J.P., et al. Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. Kaohsiung J. Med. Sci. 29 (2013), 265–270.
    • (2013) Kaohsiung J. Med. Sci. , vol.29 , pp. 265-270
    • Lin, T.H.1    Tsai, C.D.2    Pan, J.P.3    Hou, C.J.4    Hsia, C.H.5    Tsai, J.P.6
  • 56
    • 67549116889 scopus 로고    scopus 로고
    • Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study
    • [56] Mourad, J.J., Jeune, S., Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig., 2009, 419–425.
    • (2009) Clin. Drug Investig. , pp. 419-425
    • Mourad, J.J.1    Jeune, S.2
  • 57
    • 73849138948 scopus 로고    scopus 로고
    • A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study
    • [57] Ogihara, T., Saruta, T., Shimada, K., Kuramoto, K., A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. Hypertens. Res. 32 (2009), 1148–1154.
    • (2009) Hypertens. Res. , vol.32 , pp. 1148-1154
    • Ogihara, T.1    Saruta, T.2    Shimada, K.3    Kuramoto, K.4
  • 58
    • 74349114056 scopus 로고    scopus 로고
    • Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use
    • [58] Oparil, S., Lee, J., Karki, S., Melino, M., Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J. Cardiovasc. Pharmacol. 54 (2009), 427–436.
    • (2009) J. Cardiovasc. Pharmacol. , vol.54 , pp. 427-436
    • Oparil, S.1    Lee, J.2    Karki, S.3    Melino, M.4
  • 59
    • 77955251021 scopus 로고    scopus 로고
    • Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study
    • [59] Oparil, S., Melino, M., Lee, J., Fernandez, V., Heyrman, R., Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther. 32 (2010), 1252–1269.
    • (2010) Clin. Ther. , vol.32 , pp. 1252-1269
    • Oparil, S.1    Melino, M.2    Lee, J.3    Fernandez, V.4    Heyrman, R.5
  • 60
    • 84977642194 scopus 로고    scopus 로고
    • A comparative study of efficacy & safety of aliskiren as an add on therapy to olmesartan versus olmesartan monotherapy in patients with hypertension
    • [60] Rajkumar, J., Kaushal, J., Aggarwal, H.K., A comparative study of efficacy & safety of aliskiren as an add on therapy to olmesartan versus olmesartan monotherapy in patients with hypertension. Indo Global J. Pharm. Sci., 2014, 103–112.
    • (2014) Indo Global J. Pharm. Sci. , pp. 103-112
    • Rajkumar, J.1    Kaushal, J.2    Aggarwal, H.K.3
  • 61
    • 80052036781 scopus 로고    scopus 로고
    • Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension
    • [61] Rump, L.C., Girerd, X., Sellin, L., Stegbauer, J., Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J. Hum. Hypertens. 25 (2011), 565–574.
    • (2011) J. Hum. Hypertens. , vol.25 , pp. 565-574
    • Rump, L.C.1    Girerd, X.2    Sellin, L.3    Stegbauer, J.4
  • 62
    • 29244443966 scopus 로고    scopus 로고
    • Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension
    • [62] Sellin, L., Stegbauer, J., Laeis, P., Rump, L.C., Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J. Hypertens. 23 (2005), 2083–2092.
    • (2005) J. Hypertens. , vol.23 , pp. 2083-2092
    • Sellin, L.1    Stegbauer, J.2    Laeis, P.3    Rump, L.C.4
  • 63
    • 77954783076 scopus 로고    scopus 로고
    • Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study
    • [63] Shimada, K., Ogihara, T., Saruta, T., Kuramoto, K., Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Clin. Ther. 32 (2010), 861–881.
    • (2010) Clin. Ther. , vol.32 , pp. 861-881
    • Shimada, K.1    Ogihara, T.2    Saruta, T.3    Kuramoto, K.4
  • 64
    • 57449086215 scopus 로고    scopus 로고
    • Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study
    • [64] Volpe, M., Brommer, P., Haag, U., Miele, C., Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig. 29 (2009), 11–25.
    • (2009) Clin. Drug Investig. , vol.29 , pp. 11-25
    • Volpe, M.1    Brommer, P.2    Haag, U.3    Miele, C.4
  • 65
    • 84865487190 scopus 로고    scopus 로고
    • Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination
    • [65] Volpe, M., Christian Rump, L., Ammentorp, B., Laeis, P., Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin. Drug Investig. 32 (2012), 649–664.
    • (2012) Clin. Drug Investig. , vol.32 , pp. 649-664
    • Volpe, M.1    Christian Rump, L.2    Ammentorp, B.3    Laeis, P.4
  • 66
    • 67549119235 scopus 로고    scopus 로고
    • Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study
    • [66] Volpe, M., Miele, C., Haag, U., Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig. 29 (2009), 381–391.
    • (2009) Clin. Drug Investig. , vol.29 , pp. 381-391
    • Volpe, M.1    Miele, C.2    Haag, U.3
  • 67
    • 84903773938 scopus 로고    scopus 로고
    • Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension
    • [67] Volpe, M., Sierra, A., Ammentorp, B., Laeis, P., Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv. Ther., 2014, 561–574.
    • (2014) Adv. Ther. , pp. 561-574
    • Volpe, M.1    Sierra, A.2    Ammentorp, B.3    Laeis, P.4
  • 68
    • 84937574988 scopus 로고    scopus 로고
    • Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy
    • [68] Zhu, J.R., Zhang, S.Y., Gao, P.J., Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. Arch. Pharm. Res. 37 (2014), 1588–1598.
    • (2014) Arch. Pharm. Res. , vol.37 , pp. 1588-1598
    • Zhu, J.R.1    Zhang, S.Y.2    Gao, P.J.3
  • 69
    • 84880015206 scopus 로고    scopus 로고
    • 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
    • [69] Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Bohm, M., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31 (2013), 1281–1357.
    • (2013) J. Hypertens. , vol.31 , pp. 1281-1357
    • Mancia, G.1    Fagard, R.2    Narkiewicz, K.3    Redon, J.4    Zanchetti, A.5    Bohm, M.6
  • 70
    • 0036672238 scopus 로고    scopus 로고
    • A population-based European cohort study of persistence in newly diagnosed hypertensive patients
    • [70] Hasford, J., Mimran, A., Simons, W.R., A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J. Hum. Hypertens. 16 (2002), 569–575.
    • (2002) J. Hum. Hypertens. , vol.16 , pp. 569-575
    • Hasford, J.1    Mimran, A.2    Simons, W.R.3
  • 71
    • 77149122711 scopus 로고    scopus 로고
    • Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data
    • [71] Boersma, C., Voors, A.A., Visser, S.T., de Jong-van den Berg, L.T., Postma, M.J., Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data. Am. J. Cardiovasc. Drugs. 10 (2010), 49–54.
    • (2010) Am. J. Cardiovasc. Drugs. , vol.10 , pp. 49-54
    • Boersma, C.1    Voors, A.A.2    Visser, S.T.3    de Jong-van den Berg, L.T.4    Postma, M.J.5
  • 72
    • 0037232826 scopus 로고    scopus 로고
    • Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan
    • [72] Simons, W.R., Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. PharmacoEconomics 21 (2003), 61–74.
    • (2003) PharmacoEconomics , vol.21 , pp. 61-74
    • Simons, W.R.1
  • 73
    • 55549114333 scopus 로고    scopus 로고
    • Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model
    • [73] Saito, I., Kobayashi, M., Matsushita, Y., Mori, A., Kawasugi, K., Saruta, T., Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens. Res. 31 (2008), 1373–1383.
    • (2008) Hypertens. Res. , vol.31 , pp. 1373-1383
    • Saito, I.1    Kobayashi, M.2    Matsushita, Y.3    Mori, A.4    Kawasugi, K.5    Saruta, T.6
  • 74
    • 77952533332 scopus 로고    scopus 로고
    • Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension
    • [74] Miller, L.A., Wade, R., Dai, D., Cziraky, M.J., Ramaswamy, K., Panjabi, S., Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Curr. Med. Res. Opin. 26 (2010), 1307–1320.
    • (2010) Curr. Med. Res. Opin. , vol.26 , pp. 1307-1320
    • Miller, L.A.1    Wade, R.2    Dai, D.3    Cziraky, M.J.4    Ramaswamy, K.5    Panjabi, S.6
  • 75
    • 80052753077 scopus 로고    scopus 로고
    • Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens
    • [75] Belsey, J.D., Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens. J. Med. Econ. 14 (2011), 553–561.
    • (2011) J. Med. Econ. , vol.14 , pp. 553-561
    • Belsey, J.D.1
  • 76
    • 84866326463 scopus 로고    scopus 로고
    • Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis
    • [76] Wang, L., Zhao, J.W., Liu, B., Shi, D., Zou, Z., Shi, X.Y., Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Am. J. Cardiovasc. Drugs. 12 (2012), 335–344.
    • (2012) Am. J. Cardiovasc. Drugs. , vol.12 , pp. 335-344
    • Wang, L.1    Zhao, J.W.2    Liu, B.3    Shi, D.4    Zou, Z.5    Shi, X.Y.6
  • 77
    • 16644396876 scopus 로고    scopus 로고
    • Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies
    • [77] Ram, C.V., Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J. Clin. Hypertens. (Greenwich) 6 (2004), 569–577.
    • (2004) J. Clin. Hypertens. (Greenwich) , vol.6 , pp. 569-577
    • Ram, C.V.1
  • 78
    • 84873272608 scopus 로고    scopus 로고
    • Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals
    • [78] Basile, J., Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals. Integr Blood Press Control, 3, 2010, 91–104.
    • (2010) Integr Blood Press Control , vol.3 , pp. 91-104
    • Basile, J.1
  • 79
    • 79551541604 scopus 로고    scopus 로고
    • Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension
    • [79] Deeks, E.S., Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension. Drugs, 2011, 209–220.
    • (2011) Drugs , pp. 209-220
    • Deeks, E.S.1
  • 80
    • 33846931415 scopus 로고    scopus 로고
    • Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
    • [80] Greathouse, M., Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vasc. Health Risk Manag. 2 (2006), 401–409.
    • (2006) Vasc. Health Risk Manag. , vol.2 , pp. 401-409
    • Greathouse, M.1
  • 81
    • 79961196737 scopus 로고    scopus 로고
    • Olmesartan/amlodipine: a review of its use in the management of hypertension
    • [81] Kreutz, R., Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc. Health Risk Manag. 7 (2011), 183–192.
    • (2011) Vasc. Health Risk Manag. , vol.7 , pp. 183-192
    • Kreutz, R.1
  • 82
    • 84866497260 scopus 로고    scopus 로고
    • Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
    • [82] Punzi, H.A., Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination. Integr Blood Press Control, 4, 2011, 73–83.
    • (2011) Integr Blood Press Control , vol.4 , pp. 73-83
    • Punzi, H.A.1
  • 83
    • 60249093548 scopus 로고    scopus 로고
    • Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension
    • [83] Ruilope, L.M., Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension. Vasc. Health Risk Manag. 4 (2008), 1237–1248.
    • (2008) Vasc. Health Risk Manag. , vol.4 , pp. 1237-1248
    • Ruilope, L.M.1
  • 84
    • 66049134201 scopus 로고    scopus 로고
    • Olmesartan medoxomil/amlodipine
    • [84] Sanford, M., Keam, S.J., Olmesartan medoxomil/amlodipine. Drugs 69 (2009), 717–729.
    • (2009) Drugs , vol.69 , pp. 717-729
    • Sanford, M.1    Keam, S.J.2
  • 85
    • 44949171907 scopus 로고    scopus 로고
    • Olmesartan medoxomil: a review of its use in the management of hypertension
    • [85] Scott, L.J., McCormack, P.L., Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 68 (2008), 1239–1272.
    • (2008) Drugs , vol.68 , pp. 1239-1272
    • Scott, L.J.1    McCormack, P.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.